Drug Shortage Report for DALACIN C PHOSPHATE

Last updated on 2023-05-09 History
Report ID 134268
Drug Identification Number 00260436
Brand name DALACIN C PHOSPHATE
Common or Proper name Dalacin C Phosphate
Company Name PFIZER CANADA ULC
Market Status MARKETED
Active Ingredient(s) CLINDAMYCIN
Strength(s) 150MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 25 x 4mL vial
ATC code J01FF
ATC description MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-06-14
Estimated end date 2023-04-30
Actual end date 2023-05-05
Shortage status Resolved
Updated date 2023-05-09
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 17300 TRANS-CANADA HIGHWAY
KIRKLAND, QUEBEC
CANADA H9J 2M5
Company contact information Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v16 2023-05-09 French Compare
v15 2023-05-09 English Compare
v14 2023-03-16 French Compare
v13 2023-03-16 English Compare
v12 2021-12-10 French Compare
v11 2021-12-10 English Compare
v10 2021-06-15 French Compare
v9 2021-06-15 English Compare
v8 2021-06-02 French Compare
v7 2021-06-02 English Compare
v6 2021-05-06 French Compare
v5 2021-05-06 English Compare
v4 2021-02-17 French Compare
v3 2021-02-17 English Compare
v2 2021-02-17 French Compare
v1 2021-02-17 English Compare

Showing 1 to 16 of 16